7280-37-7C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=OHZEQBCVBILBTEP-ZFINNJDLSA-NEstropipate can cause cancer and developmental toxicity according to state or federal government labeling requirements.
7280-37-7DTXSID3023005CHEMBL1200980CHEBI:4873FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H302 (61.9%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P263, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 63 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Estropipate
Ambiguous-DILI-concern
2
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
용도Estropipate is used in post-menopausal women for hormonal replacement therapy, with benefits to improved cognition and prevention of osteoporosis.
일반 설명All the estrone 3-sulfate salts have the obvious pharmaceuticaladvantage of increased water solubility and better oralavailability. Acids convert the salts to the free 3-sulfate estersand cause some hydrolysis of the ester. This does not seem toaffect absorption adversely, but precipitation of the free sulfateesters in acidic pharmaceutical preparations should beavoided. The dibasic piperazine molecule acts as a buffer,giving it somewhat greater stability.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…